Epiphany Biosciences to Continue Phase 2 Shingles Study After Interim …
SAN FRANCISCO , Sept. 9 /PRNewswire/ — Epiphany Biosciences, Inc. today announced that a Phase 2b dose-ranging study to evaluate the safety, efficacy, and tolerability of the company’s lead compound, …
If you enjoyed this post, make sure you subscribe to my RSS feed!
